drugset / Trial / NCT03769532
MRD-guided Treatment in NPM1mut AML Patients
NaSingle-groupOpen-labelTreatment
Summary
Evaluation the safety and efficacy of Pembrolizumab (PEM) when administered in combination with standard Azacitidine (AZA) in nucleophosmin (NPM1) mutated AML patients with molecular relapse defined by the presence of measurable residual disease (MRD).
Timeline
- Start
- 2019-08-21
- Primary completion
- 2025-02-13
- Completion
- 2025-02-13
Outcome
Outcome not reported
Stopped: “Feasibility”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |